<i>Trypanosoma cruzi</i>Infection and Host Lipid Metabolism

Miao, Qianqian; Ndao, Momar

doi:10.1155/2014/902038

Cited by 29 publications

(22 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent mouse study showed that T. cruzi induces a disruption of cholesterol homeostasis which may play an important role in the development of different disorders seen in Chagas disease. 8 In our study, we observed that AI increased as disease severity progressed, reaching its highest values in CCHD III cases.…”

Section: Resultssupporting

confidence: 54%

The potential influence of atherogenic dyslipidemia on the severity of chronic Chagas heart disease

Peverengo

Rodeles

Vicco

et al. 2016

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Introduction: chronic Chagas heart disease (CCHD) is the most common manifestation of American Trypanosomiasis, causing about 50,000 deaths annually. Several factors bear correlation with the severity of CCHD. However, to our knowledge, the assessment on the contribution of major cardiovascular risk factors (CRF), such as hypertension and atherogenic dyslipidemia (AD) to CCHD severity is scarce, despite their well-established role in coronary artery disease, heart failure and stroke. Objective: to explore the potential relationship of blood pressure and AD with the clinical profile of patients with CCHD. Methods: we performed a cross-sectional study in T. cruzi seropositive patients categorized according to a standard CCHD classification. All individuals were subjected to complete clinical examination. Autoantibodies induced by T. cruzi were assessed by ELISA. Results: we observed that Atherogenic index (AI) levels rose significantly in relation to the severity of the CCHD stage, with CCHD III cases showing the highest values of AI. Furthermore, those patients with globally dilated cardiomyopathy with reduced ejection fraction showed higher levels of AI. In regard to autoantibodies, anti-B13 also showed relation with the severity of the disease. Conclusion: we observed that AI correlated with CCHD stages and contributed, in association with anti-B13 antibodies and age, to the prediction of systolic heart failure.

show abstract

Section: Resultssupporting

confidence: 54%

The potential influence of atherogenic dyslipidemia on the severity of chronic Chagas heart disease

Peverengo

Rodeles

Vicco

et al. 2016

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…T. cruzi has high affinity for cholesterol (LDL and HDL) and uses LDL receptors and scavenger receptors to invade various host cells [7, 8, 16, 17]. We measured LDL receptor levels in WAT (d 10pi) and heart (d 20pi) at early acute phase and active acute phase respectively since at these respective time points we observed significant initiation of pathological changes in these tissues (these time points were also chosen to avoid loss of animals due to death from infection) [4, 8].…”

Section: Discussionmentioning

confidence: 99%

Antagonistic effect of atorvastatin on high fat diet induced survival during acute Chagas disease

Zhao

Lizardo

Cui

et al. 2016

Microbes and Infection

View full text Add to dashboard Cite

Chagasic cardiomyopathy, which is seen in Chagas Disease, is the most severe and life-threatening manifestation of infection by the kinetoplastid Trypanosoma cruzi. Adipose tissue and diet play a major role in maintaining lipid homeostasis and regulating cardiac pathogenesis during the development of Chagas cardiomyopathy. We have previously reported that T. cruzi has a high affinity for lipoproteins and that the invasion rate of this parasite increases in the presence of cholesterol, suggesting that drugs that inhibit cholesterol synthesis, such as statins, could affect infection and the development of Chagasic cardiomyopathy. The dual epidemic of diabetes and obesity in Latin America, the endemic regions for Chagas Disease, has led to many patients in the endemic region of infection having hyperlipidemia that is being treated with statins such as atorvastatin. The current study was performed to examine using mice fed on either regular or high fat diet the effect of atorvastatin on T. cruzi infection-induced myocarditis and to evaluate the effect of this treatment during infection on adipose tissue physiology and cardiac pathology. Atorvastatin was found to regulate lipolysis and cardiac lipidopathy during acute T. cruzi infection in mice and to enhance tissue parasite load, cardiac LDL levels, inflammation, and mortality in during acute infection. Overall, these data suggest that statins, such as atorvastatin, have deleterious effects during acute Chagas disease.

show abstract

“…Finally, considering the evidence that associates T. cruzi with the adipose tissue, ApoA1 and with HDL and LDL modifications, as well as its interaction with LDL receptors [95], the serum lipid profile is an interesting and important metabolome component in the search for possible CD biomarkers. Lipidomics has been defined as "the full characterization of lipid molecular species and of their biological roles with respect to expression of proteins involved in lipid metabolism and function, including gene regulation."…”

Section: Omics-based Applicationsmentioning

confidence: 99%

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

2019

Self Cite

View full text Add to dashboard Cite

Chagas disease (CD), caused by Trypanosoma cruzi, affects millions of people worldwide. Although CD R&D has made progress during the last decade, clinicians and general practitioners are still facing the same challenge, i.e., the lack of adequate markers of clinical cure, hindering assessment of new drug efficacy in clinical trials and counseling of patients about treatment outcome. To date, no new markers have been validated as surrogates of seroreversion-the only marker of parasitological cure which is itself considered to be a surrogate of clinical benefit. T. cruzi DNA detected using PCR cannot currently be considered as a surrogate of seroconversion. Much emphasis has been placed on different T. cruzi antigens but no definite proof of correlation between titers, as determined by serology at a given timepoint, and seroreversion has been shown. Thanks to the improvement of analytical methods and the application of new methodologies, the identification of potential new markers is being facilitated, and some of these are progressing. However, there is a long journey from the identification of a potential biomarker to its clinical validation and acceptance by the regulatory authorities that requires a common effort from the entire Chagas community.

show abstract

Trypanosoma cruziInfection and Host Lipid Metabolism

Cited by 29 publications

References 108 publications

The potential influence of atherogenic dyslipidemia on the severity of chronic Chagas heart disease

The potential influence of atherogenic dyslipidemia on the severity of chronic Chagas heart disease

Antagonistic effect of atorvastatin on high fat diet induced survival during acute Chagas disease

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

Contact Info

Product

Resources

About